Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › finasteride

finasteride

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of finasteride

10 trials tracked of finasteride: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 13 citations.

10Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 6 Phase 1 1
  1. Phase 4 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed · 13 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Completed
  3. Phase 3 A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Completed
  4. Phase 2 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed
  5. Phase 2 Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed
  6. Phase 2 A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed
Show 4 more trials
  1. Phase 2 Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery Completed
  2. Phase 2 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed
  3. Phase 2 5-Alpha Reductase and Anabolic Effects of Testosterone Completed
  4. Phase 1 ORAL T-6: Oral Androgens in Man-6 Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
5-alpha-reductase inhibitors show no statistically significant association with suicide or neuropsychiatric events in BPH or AGA
Urology Meta-analysis
5-alpha-reductase inhibitors show no statistically significant association with suicide or neuropsychiatric events in BPH or AGA Trial shows 5-alpha-reductase inhibitors do not increase suicide risk
This meta-analysis of observational studies examined the risk of suicide and neuropsychiatric events in patients with benign prostatic hyper…
New data suggests that 5-alpha-reductase inhibitors for hair loss or prostate issues are not linked to higher rates of suicide or depression…
Frontiers Oct 5, 2026
5-alpha-reductase inhibitors are associated with increased sexual adverse events in androgenetic alopecia patients
Oncology Meta-analysis
5-alpha-reductase inhibitors are associated with increased sexual adverse events in androgenetic alopecia patients Hair loss medications may cause some side effects for men
This systematic review of 41 studies evaluates the impact of finasteride and dutasteride on sexual dysfunction in patients with hair loss. T…
Men using finasteride or dutasteride for hair loss may experience sexual side effects, though most cases are mild and reversible when the dr…
Frontiers Jun 29, 2026
Retrospective analysis of 41,775 reports identifies signals for cognitive disorders with 50 medications including finasteride and diltiazem
Drug Pipeline Cohort
Retrospective analysis of 41,775 reports identifies signals for cognitive disorders with 50 medications including finasteride and diltiazem Analysis of 50 drugs shows statistical links to cognitive issues in vulnerable groups
This retrospective disproportionality analysis examined 41,775 reports from the FDA, JADER, and WHO VigiAccess databases (2004–2024) involvi…
74% of 50 drugs linked to cognitive issues in reports lack FDA warnings, with signals stronger in vulnerable groups like children and senior…
Frontiers Apr 19, 2026